LNTH | Ticker Profile - Titan Protect

LNTH

Lantheus Holdings, Inc.

Healthcare · Drug Manufacturers - Specialty & Generic · NGM

$100.98

Data: 2026-05-28

✓ ETHICAL PASS

Unknown MOAT

HIGH

Data Confidence: 100.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$6.5B

Total market value of the company

Trailing P/E

23.65

Premium valuation

Forward P/E

15.54

Based on estimated future earnings — lower means cheaper

Rev Growth

+1.2%

Year-over-year revenue change

Profit Margin

18.0%

How much profit the company keeps from each dollar of revenue

ROE

23.5%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$105.00

+4% from current price — median analyst estimate

Recommendation

STRONG_BUY

Consensus view from 13 analysts covering this stock

About Lantheus Holdings, Inc.

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide. The company offers DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. It also provides Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; PYLARIFY AI, an medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer; and flurpiridaz used to assess blood flow to the heart. In addition, it develops PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy to patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent for Tau tangles in Alzheimer's disease; LNTH-2401, a novel radiodiagnostic targeting the gastrin-releasing peptide receptor; LNTH-2402; LNTH-2403; LNTH-2404; LNTH-250; LNTH-2515; and LNTH-1363S, an fibroblast activation protein, alpha, copper-64 labeled PET imaging agent. It has collaboration agreements with GE Healthcare; Curium Pharma; POINT; Regeneron; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.

https://www.lantheus.com

Country: United States Employees: 1,193 Industry: Drug Manufacturers - Specialty & Generic

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% N/A

Debt must be below 33% of total assets

Cash Ratio

0.0% N/A

Interest-bearing cash below 33% of assets

Receivables

0.0% N/A

Receivables below 49% of assets

Revenue Purity

0.0% PASS

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKUP

Price trending up with increasing momentum

Sharpe Ratio

0.484

Positive but modest risk-adjusted returns

Kelly Fraction

0.0515

Suggested allocation is meaningful — the edge justifies a position

Calmar Ratio

0.199

Drawdown risk outweighs the returns — higher risk profile

Annual Return

11.8%

Historical annualised return based on price data

Max Drawdown

-59.5%

Largest peak-to-trough decline — the worst it has been

HMM State

SIDEWAYS

Price consolidating — no clear directional bias

Days in State

183

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

-0.08

Very low correlation to market moves

52W High

$103.89

3% below the year high

52W Low

$47.25

114% above the year low

Avg Volume

1,008,827

Average daily shares traded — higher means easier to buy and sell

Short Ratio

7.2

Days it would take all short sellers to cover — higher means more crowded

Short % Float

13.2%

Elevated short interest — bears are positioned against this

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$4.19

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

51.62

Heavy leverage — higher financial risk if revenues decline

Current Ratio

2.83

Strong balance sheet — comfortably covers short-term obligations

Quick Ratio

2.57

Like current ratio but excludes inventory — stricter test

Gross Margin

60.5%

Revenue left after cost of goods — higher means pricing power

Operating Margin

21.6%

Profit from core operations before interest and tax

Free Cash Flow

$422M

Positive — the business generates more cash than it spends

Revenue (TTM)

$1.5B

Total revenue over the last 12 months

Net Income

$279M

Profitable — the bottom line is positive

Analyst Coverage

Analysts

Target High

$117.00

Target Median

$105.00

Target Low

$76.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-28

Before you go